ReviewCureus2026
Efficacy of Risankizumab in Moderate to Severe Psoriasis Considering Body Mass Index: A Scoping Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin disease that significantly impacts patients quality of life and is frequently associated with obesity. This comorbidity may influence disease progression and treatment outcomes. Risankizumab, an interleukin-23 (IL-23) inhibitor, has demonstrated high efficacy in treating moderate to severe plaque psoriasis. However, its performance in obese patients remains unclear due to conflicting data. This scoping review aims to evaluate the impact of obesity, specifically BMI ≥ 30 kg/m², on the efficacy and safety of risankizumab in adults with moderate to severe plaque psoriasis. A comprehensive literature search was carried out in databases including PubMed, Scopus, JAMA, Elsevier, and Wiley, between December 2024 and February 2025. The selection included studies from 2020 to 2025, focusing on Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) outcomes in psoriatic patients receiving risankizumab, with or without obesity. 24 articles were included and analyzed by study design, patient characteristics, treatment response, and BMI influence. Risankizumab consistently demonstrated strong efficacy and safety in reducing PASI scores and improving DLQI across all BMI categories. While most studies reported no significant difference in response due to BMI, some suggested enhanced early responses in non-obese patients. Continuous treatment showed long-term benefits regardless of BMI, with 90% or greater improvement in the PASI (PASI90) and complete clearance (PASI100) maintained up to five years. Risankizumab is a highly effective and safe biologic therapy for moderate to severe psoriasis, even in patients across all BMI. Although some variations in response exist, the overall evidence supports its use across diverse patient profiles. Weight management should still be considered a complementary strategy in psoriasis care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.